Results 31 to 40 of about 47,373 (236)
Aripiprazole salts. I. Aripiprazole nitrate
Acta Crystallographica Section C Crystal Structure Communications, 2012 The crystal structure of aripiprazole nitrate (systematic name: 4-(2,3-dichlorophenyl)-1-{4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl}piperazin-1-ium nitrate), C23H28Cl2N3O2+·NO3−or AripH+·NO3−, is presented and the molecule compared with the aripiprazole molecules reported so far in the literature. Bond distances and angles appear very similar,
Freire Espeleta, Eleonora +2 more
openaire +3 more sources
Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study
Scientific Reports, 2022 The dopamine blockade by antipsychotics trigger subjective dysphoria. Compared with D2 antagonists, aripiprazole, a D2 partial agonist, was expected to produce a different experience.
Seoyoung Kim +3 more
doaj +1 more source
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder [PDF]
, 2018 This document is an Accepted Manuscript reprinted from Journal of Addiction Medicine, Vol. 12 (3): 247-251, May 2018, with permission of Kluwer Law International. Under embargo until 1 May 2019.
Calabrò, Giuseppa +9 more
core +2 more sources
Aripiprazole salts. II. Aripiprazole perchlorate
Acta Crystallographica Section C Crystal Structure Communications, 2012 The molecular structure of aripiprazole perchlorate (systematic name: 4-(2,3-dichlorophenyl)-1-{4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl}piperazin-1-ium perchlorate), C23H28Cl2N3O2+·ClO4−, does not differ substantially from the recently published structure of aripiprazole nitrate [Freire, Polla & Baggio (2012).Acta Cryst.C68, o170–o173].
Freire Espeleta, Eleonora +2 more
openaire +3 more sources
ARIPIPRAZOLE INDUCED COMPULSIVE EATING DISORDER: A CASE REPORT
European Psychiatry, 2023 Introduction Aripiprazole is a newer atypical antipsychotic with a favorable side-effect profile, especially a low propensity to result in metabolic syndromes.It is effective at treating bipolar disorder, the positive symptoms of schizophrenia and has ...
M. Turki +6 more
doaj +1 more source
Five-year patient outcomes with risperidone long-acting injection or oral aripiprazole [PDF]
, 2015 Background: This study examined 5-year outcomes of patients prescribed risperidone long-acting injection (RLAI) or aripiprazole in a clinical setting, using treatment discontinuation as a measure of effectiveness.
Deslandes, Paul +2 more
core +2 more sources
Journal of Pharmacological Sciences, 2008 Aripiprazole, an atypical antipsychotic drug, is a D2dopamine–receptor partial agonist, but also has affinity to several serotonin receptors (5-HT1A,2A,2C,7).
Shuntaro Kohnomi +3 more
doaj +1 more source
Urinary retention in male patient associated with aripiprazole
Medicine Science, 2016 Urinary retention and / or voiding difficulty are a rare side effect caused by the second generation antipsychotics. Aripiprazole has a lower incidence of adverse effects than other second generation antipsychotics (SGA) and aripiprazole can be used as ...
Lara Utku Ince +2 more
doaj +1 more source
Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. [PDF]
PLoS ONE, 2013 ObjectiveTo compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.MethodsPopulationadult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with ...
Xianbin Li, Yilang Tang, Chuanyue Wang
doaj +1 more source
Journal of Experimental Neuroscience, 2015 Aripiprazole is a third-generation atypical antipsychotic and a dopamine D 2 receptor partial agonist. In the present study, we investigated whether a single administration of aripiprazole to mice, either as a pretreatment or as a posttreatment, would ...
Nobue Kitanaka +6 more
doaj +1 more source